Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial

Xuewei Xie,Jing Jing,Xia Meng,S. Claiborne Johnston,Philip M. Bath,Zixiao Li,Xingquan Zhao,Liping Liu,Yilong Wang,Qin Xu,Anxin Wang,Yong Jiang,Hao Li,Yongjun Wang,Yongjun Wang,S. Claiborne Johnston,Anding Xu,Philip M. W. Bath,Qiang Dong,Yongjun Wang,Hao Li,Xia Meng,Jing Jing,Xuewei Xie,Jinxi Lin,Tabassome Simon,Nicolas Danchin,Helen Zhi,Bin Peng,Dongsheng Fan,David Wang,Teddy Youn,Harold P. Adams,Xia Meng,Xuewei Xie,Jing Jing,Jinxi Lin,Siying Niu,Hao Li,Yuesong Pan,Anxin Wang,Yong Jiang,Aoming Jin,Haibo Wu,Wei Shi,Haibo Wu,Jianhua Li,Yanxia Wang,Yan Wei,Haichao Liu,Jianhua Zhao,Xinshen Han,Baoying Sheng,Xiaofan Yang,Ping Jing,Jiechun Chen,Panbing Huang,Guofang Chen,Yefang Feng,Lie Wu,Runxiu Zhu,Peiru Liu,Liguo Chang,Xiafeng Yang,Xinqiang Wang,Jinguo Zhao,Wei Zhang,Zhigang Cui,Xuemei Wu,Hua Huang,Qiuwu Liu,Xingquan Zhao,Dongli Cheng,Yulan Zhu,Lihua Wang,Guozhong Li,Xiaoxuan Zhang,Wenjun Xue,Guohua Chen,Haipeng Li,Ke Deng,Jingyao Liu,Yansong Liu,Xiu’e Wei,Dunjing Wang,Juan Feng,Baojun Wang,Yongming Chen,Bing Wu,Xiangting Chai,Fudong Shi,Xueli Cai,Hongqin Yang,Yundong Zhang,Xia Wang,Yumei Wang,Zhimin Shi,Shengli Chen,Yangmei Chen,Lichun Zhou,Weimin Hong,Lufeng Yin,Lijie Ren,Jianhua Ma,Yongqian Lei,Minghua Wu,Guoyong Zeng,Lingfeng Wu,Mingha Cao,Cunju Guo,Honghao Man,Yu Bai,Aimei Wu,Xuerong Huang,Chunhua Zhang,Xiaoling Jiang,Peining Shao,Dexin Luo,Zhiyou Cai,Yi Jia,Aijun Ma,Ying Bai,Xuhai Gong,Jirong Liu,Meng Zhang,Anding Xu,Hong Tan,Yi An,Zhimin Wang,Weili Zhao,Xiangbin Wu,Wenwei Gao,Yueqiang Gao,Xinyi Li,Jin Wu,Feng Wang,Ganqin Du,Kaiyi Wu,Hebin Wan,Lan Chu,Daojun Hong,Hui Cao,Bing Xu,Jie Liu,Hao Zhang,Jie Yang,Guiru Zhang,Hong Chen,Jianling Zhang,Xuemei Li,Yu’an Zou,Yan Wang,Xia Wei,Jianlin Wang,Weifeng Chen,Chunfeng Liu,Changbai Sui,Hongyan Li,Hua Zhong,Aisheng Wu,Jinqi Fan,Qiuhong Ji,Jinshen Lin,Xueying Shi,Guangming Kang,Haiyang Xie,Dan Ma,Hongliang Wang,Wei Chen,Peng Shi,Wen Shangguan,Jun Gu,Xiaopeng Feng,Qunling Zhan,Xianwen Han,Hongyuan Cao,Liang Wei,Weifeng Lu,Chunling Zheng,Chunjie Yang,Min Zhao,Heng Wu,Chunhua Dong,Yongli He,Shufang Yao,Xiangyang Zhu,Zhong Zhao,Min Ye,Guodong Cai,Guangyao Peng,Hongfei Li,Lujun Zhang,Shoucheng Zhang,Wei Zhou,Hong Liu,Xuewen Fan,Wei Tan,Renxiang Zhu,Tianhui He,Qizhang Wang,Lifang Zhang,Jinsuo Yang,Yuqing Liu,Shaohua Su,Li He,Yadong Yu,Zhang Wei,Lin Zhankui,Xue Rong Qiu,Ying Bin Qi,Lei Sheng,Shi Zheng Wu,Song Di Wu,Sheng Liang Wu,Ding Qin,Bo Xiao,Kai Wang,Xi Ting Zhang,Jin Jing Pang,Xuewei XieJing JingXia MengS. Claiborne JohnstonPhilip M. BathZixiao LiXingquan ZhaoLiping LiuYilong WangQin XuAnxin WangYong JiangHao LiYongjun WangChina National Clinical Research Center for Neurological Diseases,Beijing (X.X.,J.J.,X.M.,Z.L.,X.Z.,L.L.,Q.X.,A.W.,Y.J.,H.L.,Yongjun Wang).Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,China (X.X.,J.J.,X.M.,Z.L.,X.Z.,L.L.,Q.X.,A.W.,Y.J.,H.L.,Yongjun Wang).Tiantan Neuroimaging Center of Excellence,Beijing,China (J.J.).Department of Neurology,University of California,San Francisco (S.C.J.).Stroke Trials Unit,Mental Health and Clinical Neuroscience,University of Nottingham,United Kingdom (P.M.B.).,for the CHANCE-2 Investigators Yongjun Wang S. Claiborne Johnston Anding Xu Philip M. W. Bath Qiang Dong Yongjun Wang Hao Li Xia Meng Jing Jing Xuewei Xie Jinxi Lin Tabassome Simon Nicolas Danchin Helen Zhi Bin Peng Dongsheng Fan David Wang Teddy Youn Harold P. Adams Xia Meng Xuewei Xie Jing Jing Jinxi Lin Siying Niu Hao Li Yuesong Pan Anxin Wang Yong Jiang Aoming Jin Haibo Wu Wei Shi Haibo Wu Jianhua Li Yanxia Wang Yan Wei Haichao Liu Jianhua Zhao Xinshen Han Baoying Sheng Xiaofan Yang Ping Jing Jiechun Chen Panbing Huang Guofang Chen Yefang Feng Lie Wu Runxiu Zhu Peiru Liu Liguo Chang Xiafeng Yang Xinqiang Wang Jinguo Zhao Wei Zhang Zhigang Cui Xuemei Wu Hua Huang Qiuwu Liu Xingquan Zhao Dongli Cheng Yulan Zhu Lihua Wang Guozhong Li Xiaoxuan Zhang Wenjun Xue Guohua Chen Haipeng Li Ke Deng Jingyao Liu Yansong Liu Xiu'e Wei Dunjing Wang Juan Feng Baojun Wang Yongming Chen Bing Wu Xiangting Chai Fudong Shi Xueli Cai Hongqin Yang Yundong Zhang Xia Wang Yumei Wang Zhimin Shi Shengli Chen Yangmei Chen Lichun Zhou Weimin Hong Lufeng Yin Lijie Ren Jianhua Ma Yongqian Lei Minghua Wu Guoyong Zeng Lingfeng Wu Mingha Cao Cunju Guo Honghao Man Yu Bai Aimei Wu Xuerong Huang Chunhua Zhang Xiaoling Jiang Peining Shao Dexin Luo Zhiyou Cai Yi Jia Aijun Ma Ying Bai Xuhai Gong Jirong Liu Meng Zhang Anding Xu Hong Tan Yi An Zhimin Wang Weili Zhao Xiangbin Wu Wenwei Gao Yueqiang Gao Xinyi Li Jin Wu Feng Wang Ganqin Du Kaiyi Wu Hebin Wan Lan Chu Daojun Hong Hui Cao Bing Xu Jie Liu Hao Zhang Jie Yang Guiru Zhang Hong Chen Jianling Zhang Xuemei Li Yu'an Zou Yan Wang Xia Wei Jianlin Wang Weifeng Chen Chunfeng Liu Changbai Sui Hongyan Li Hua Zhong Aisheng Wu Jinqi Fan Qiuhong Ji Jinshen Lin Xueying Shi Guangming Kang Haiyang Xie Dan Ma Hongliang Wang Wei Chen Peng Shi Wen Shangguan Jun Gu Xiaopeng Feng Qunling Zhan Xianwen Han Hongyuan Cao Liang Wei Weifeng Lu Chunling Zheng Chunjie Yang Min Zhao Heng Wu Chunhua Dong Yongli He Shufang Yao Xiangyang Zhu Zhong Zhao Min Ye Guodong Cai Guangyao Peng Hongfei Li Lujun Zhang Shoucheng Zhang Wei Zhou Hong Liu Xuewen Fan Wei Tan Renxiang Zhu Tianhui He Qizhang Wang Lifang Zhang Jinsuo Yang Yuqing Liu Shaohua Su Li He Yadong Yu Zhang Wei Lin Zhankui Xue Rong Qiu Ying Bin Qi Lei Sheng Shi Zheng Wu Song Di Wu Sheng Liang Wu Ding Qin Bo Xiao Kai Wang Xi Ting Zhang Jin Jing Pang
DOI: https://doi.org/10.1161/strokeaha.122.042233
IF: 10.17
2023-08-08
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:It is unclear whether patients with different stroke/transient ischemic attack etiologies benefit differently from gene-directed dual antiplatelet therapy. This study explored the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in transient ischemic attack or minor stroke with different causes in the CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II).METHODS:This was a prespecified analysis of the CHANCE-2 trial, which enrolled 6412 patients with minor stroke or transient ischemic attack who carriedCYP2C19loss-of-function alleles. Patients with centralized evaluation of TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification of large-artery atherosclerosis, small-vessel occlusion, and stroke of undetermined cause were included. The primary efficacy outcome was new stroke, and the primary safety outcome was severe or moderate bleeding, both within 90 days. Cox proportional hazards models were used to assess the interaction of TOAST classification with the effects of dual antiplatelet therapy with ticagrelor-aspirin versus clopidogrel-aspirin.RESULTS:A total of 6336 patients were included in this study. In patients administered ticagrelor-aspirin and clopidogrel-aspirin, respectively, stroke recurred in 85 (9.8%) and 88 (10.7%) patients with large-artery atherosclerosis (hazard ratio, 0.86 [95% CI, 0.63–1.18];P=0.34); 32 (3.6%) and 61 (7.0%) patients with small-vessel occlusion (hazard ratio, 0.51 [95% CI, 0.33–0.79];P=0.002); and 68 (4.8%) and 87 (5.9%) patients with stroke of undetermined cause (hazard ratio, 0.80 [95% CI, 0.58–1.10];P=0.17), withP=0.08 for the treatment×cause subtype interaction effect. There were no significant differences in severe or moderate bleeding events in patients with different cause and different treatment.CONCLUSIONS:In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL:https://www.clinicaltrials.gov; Unique identifier: NCT04078737.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?